Abbott Laboratories: When Double-Digit Device Growth Apparently Isn’t Enough
Summary: Abbott Labs has continued to lag competitors like Boston Scientific and Stryker that are
Summary: Abbott Labs has continued to lag competitors like Boston Scientific and Stryker that are
Summary: The S&P 500 gained 2% last week despite weak employment data and manufacturing sentiment,
Summary: Wall Street analysts have a ‘strong buy’ rating on ABT stock, with 12 out
Summary: Abbott Laboratories is one of the smaller holdings in my portfolio, but that won’t
Summary: Inflation concerns are rising in the United States, particularly in healthcare. Abbott Laboratories is
Summary: Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue.
Summary: My investment strategy is to fill my portfolio with remarkably reliable dividend growers. Abbott
Summary: ABT continues to ride the diabetes tailwinds, as the market turns increasingly optimistic about
Summary: Abbott Laboratories is back on track with a path to sustained, double-digit growth and
Summary: Abbott Laboratories’ stock price has risen by 16.6% since October 2023, outperforming the index.